Evolution of the Average Target: Axsome Therapeutics, Inc.

Evolution of the Average Target - Axsome Therapeutics, Inc.

Evolution of the Target Price: Axsome Therapeutics, Inc.

Evolution of the Target Price - Axsome Therapeutics, Inc.

Changes in Analyst Recommendations: Axsome Therapeutics, Inc.

13cda25138a7025f5b191662637eb.vBrr7TEqxLzF7cEqDREWvRllW9Lniuto-IRaSbDeSXk.ji2DjwdrvOz8jvQSQGN9zUxTOJe07p08nrw3E-mUJDbXXNLaaV709JqmlA~73de531b8ea0b9f565a35368ab1165e2
Oct. 14 Axsome Shows Valuation Disconnect Ahead of Q3, RBC Says MT
Oct. 08 RBC Trims Price Target on Axsome Therapeutics to $295 From $297, Keeps Outperform Rating MT
Sep. 29 Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating MT
Sep. 25 Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says MT
Sep. 23 Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating MT
Sep. 18 Axsome's Auvelity Launch Shows Early Strength in Alzheimer's Agitation, RBC Says MT
Sep. 01 Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says MT
Aug. 12 UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating MT
Aug. 12 Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating MT
Aug. 11 Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says MT
Aug. 11 Morgan Stanley Adjusts Axsome Therapeutics PT to $251 From $242, Keeps Equalweight Rating MT
Aug. 11 RBC Adjusts PT on Axsome Therapeutics to $297 From $304, Maintains Outperform Rating MT
Jul. 31 Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating MT
Jul. 21 BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target MT
Jul. 07 RBC Capital Adjusts Axsome Therapeutics Price Target to $304 From $302, Maintains Outperform Rating MT
May. 27 Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says MT
May. 05 B. Riley Adjusts Price Target on Axsome Therapeutics to $300 From $230, Maintains Buy Rating MT
May. 05 Mizuho Adjusts Price Target on Axsome Therapeutics to $310 From $228, Maintains Outperform Rating MT
May. 05 RBC Raises Price Target on Axsome Therapeutics to $302 From $242, Keeps Outperform Rating MT
May. 04 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
May. 04 Deutsche Bank Adjusts Axsome Therapeutics PT to $281 From $245, Maintains Buy Rating MT
Apr. 29 Mizuho Keeps Price Target on Axsome Therapeutics to $228, Maintains Outperform Rating MT
Apr. 29 Mizuho Adjusts Price Target on Axsome Therapeutics to $228 From $230, Maintains Outperform Rating MT
Apr. 28 Mizuho Securities Adjusts Axsome Therapeutics Price Target to $228 From $230, Maintains Outperform Rating MT
Apr. 21 Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+93.28%
+4.56%
+5.91%
-0.3%
-1.29%
+9.97%
-1.87%
+22.49%
-9.69%
+2.66%
Average +12.57%
Weighted average by Cap. +4.04%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
145.04USD
Average target price
280.33USD
Spread / Average Target
+93.28%
High Price Target
380.00USD
Spread / Highest target
+162.00%
Low Price Target
245.00USD
Spread / Lowest Target
+68.92%

Analyst Consensus Detail

Analyst consensus - Axsome Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Axsome Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Axsome Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. AXSM Stock
  4. Consensus Axsome Therapeutics, Inc.